Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

981. Results of conservative management of clinically localized prostate cancer. (PubMed)

Results of conservative management of clinically localized prostate cancer. The selection of treatment for patients with localized prostate cancer requires reliable information about the outcome of conservative management. Previous studies of this question are generally considered unreliable because they were uncontrolled and nonrandomized.We performed a pooled analysis of 828 case records from six nonrandomized studies, published since 1985, of men treated conservatively (with observation (...) and delayed hormone therapy but no radical surgery or irradiation) for clinically localized prostate cancer. A Cox regression analysis was performed to determine which factors influenced survival among patients who did not die of causes other than prostate cancer (disease-specific survival). Kaplan-Meier curves for overall and metastasis-free survival among such patients were compared with use of the log-rank method and the Mantel-Haenszel test.Factors that had a significant effect on disease-specific

1994 NEJM

982. Cost-effective prostate cancer detection: reduction of low-yield biopsies

Cost-effective prostate cancer detection: reduction of low-yield biopsies Cost-effective prostate cancer detection: reduction of low-yield biopsies Cost-effective prostate cancer detection: reduction of low-yield biopsies Littrup P J, Kane R A, Mettlin C J, Murphy G P, Lee F, Toi A, Badalament R, Babaian R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Digital rectal examination (DRE), transrectal ultrasound (TRUS) and prostate specific antigen (PSA)-related tests in the detection of prostate cancer. Type of intervention Screening. Economic study type Cost-effectiveness study. Study population Men undergoing testing for prostate cancer detection. Setting The practice setting was US hospitals involved in the American Cancer

1994 NHS Economic Evaluation Database.

983. Screening for prostate cancer: a decision analytic view

Screening for prostate cancer: a decision analytic view Screening for prostate cancer: a decision analytic view Screening for prostate cancer: a decision analytic view Krahn M D, Mahoney J E, Eckman M H, Trachtenberg J, Pauker S G, Detsky A S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Screening for prostate cancer with prostate-specific antigen (PSA), transrectal ultrasound (TRUS) and digital rectal examination (DRE). Type of intervention Screening/secondary prevention. Economic study type Cost-utility analysis. Study population Cohorts of men between the ages of 50 and 70. Setting Medical centre. The economic study was carried out in Ontario (Canada). Dates to which data relate Dates for effectiveness and resource

1994 NHS Economic Evaluation Database.

984. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone

A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone McEwan A J, Amyotte G A, McGowan D G, MacGillivray J (...) A, Porter A T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of strontium isotope as adjunct therapy in patients with prostate cancer metastatic tothe bone. Type of intervention Palliative care. Economic study type Cost

1994 NHS Economic Evaluation Database.

985. An economic rationale for prostate cancer screening

An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening Benoit R M, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health (...) technology (a) Screening for prostate cancer using prostate-specific antigen(PSA) testing with and without digital rectal examination(DRE) (b) Screening for breast cancer using mammography with and without clinical breast examination. Type of intervention Secondary prevention Economic study type Cost-effectiveness analysis. Study population Men aged 50 to 70 and women aged 50-69. Setting The practice setting for breast cancer screening was not specified (it might be primary care). Prostate cancer

1994 NHS Economic Evaluation Database.

986. Prostate-cancer surveillance: a cost-effective strategy

Prostate-cancer surveillance: a cost-effective strategy Prostate-cancer surveillance: a cost-effective strategy Prostate-cancer surveillance: a cost-effective strategy Schapira D V, Jarrett A R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn (...) . Health technology Surveillance strategies involving history, physical examination, complete blood cell count, chemistry panel, prostate specific antigen (PSA), and annual bone scan techniques for the earlydetection of metastases in patients who might suffer a recurrence of prostate cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Patients with local and regional prostate cancer undergoing surveillance for possible recurrence after initial

1993 NHS Economic Evaluation Database.

987. Prostatic cancer in the Nordic Countries

Prostatic cancer in the Nordic Countries Prostatic cancer in the Nordic Countries Prostatic cancer in the Nordic Countries Jonsson P M, Danneskiold-Samsoe B, Heggestad T Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jonsson P M, Danneskiold-Samsoe B, Heggestad T. Prostatic cancer in the Nordic Countries. Danish Institute for Health (...) Services Research (DSI). 1992 Authors' objectives Study in variations in diagnosis and treatment of prostatic cancer in the Nordic countries. Authors' conclusions In spite of numerous scientific trails knowledge on prostatic cancer remains limited. The beneficial effects of screening are doubtful due to the lack of evidence that early detection may lead to prolongation of life or increased quality of life. Other output or dissemination activity: Impact not evaluated. Project page URL Indexing Status

1992 Health Technology Assessment (HTA) Database.

988. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. (PubMed)

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. The independent prognostic factors affecting survival were assessed in 240 men undergoing treatment for metastatic prostate cancer as part of a randomized clinical trial comparing the gonadotropin releasing hormone analogue Zoladex (goserelin acetate implant) with castration. In a multivariate analysis, the most highly significant predictors were the presence or absence of bone pain

1991 JAMA

989. Costs and benefits of early detection of prostatic cancer

Costs and benefits of early detection of prostatic cancer Costs and benefits of early detection of prostatic cancer Costs and benefits of early detection of prostatic cancer Carlsson P, Pedersen K V, Varenhorst E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Rectal-digital examination for detecting prostate cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Men, aged 50-69 years. Setting The study was carried out in Sweden. Dates to which data relate Price related to 1989. Source of effectiveness data Single study. Modelling Epidemiological cohort model (model of survival and disease). Measure of benefits used in the economic analysis Potentially curablecases detected

1990 NHS Economic Evaluation Database.

990. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. (PubMed)

Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. In a population-based study, disease progression and survival were evaluated in untreated patients with newly diagnosed cancer of the prostate without distant metastases. Complete follow-up was achieved in 223 of 227 (98%) consecutively diagnosed, eligible patients of all ages. After 5 years, the cumulative progression-free survival (with 95% confidence interval) was 71.8 (65.5-78.1)% and survival (...) corrected for causes of death other than prostatic cancer was 93.8 (88.3-97.6)%. Univariate and multivariate analyses showed no association between age at diagnosis and the natural course. Local progression was less common in localised, non-palpable tumours than in larger tumours. The rate of progression was 18.7 (6.1-57.1) times higher and that of disease-specific death 216.0 (31.2-1496) times higher in patients with poorly than in those with highly differentiated tumours. It is concluded that tumour

1989 Lancet

991. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. (PubMed)

Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment. Initial therapy (leuprolide or DES) was continued for as long as an objective response was noted; cross-over (...) alternative treatment that is therapeutically equivalent to and causes fewer side effects than DES for the initial systemic management of metastatic prostate cancer.

1984 NEJM